

**INFORMATION
DISCLOSURE
STATEMENT**

MAR 31 2005

		<i>Complete if known</i>	
		Application Number: 09/980,913	
		Filing Date: May 21, 2002	
		First Named Inventor: Ernest Arenas, et al.	
		Group Art Unit: 1636	
		Examiner Name: Gerald G. Leffers Jr. <i>Laura Mc GILL</i>	
SHEET 1 OF 1		Attorney Docket Number: 0380-P02709US0	

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
<i>KGM</i>	A1	6,833,269 B2	12-21-2004	Carpenter

FOREIGN PATENT DOCUMENTS


EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

EXAMINER'S SIGNATURE	<i>Laura Mc GILL</i>	DATE CONSIDERED	7/13/08
----------------------	----------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT

Complete if known			
Application Number: 09/980,913			
Filing Date: May 21, 2002			
First Named Inventor: Ernest Arenas, et al.			
Group Art Unit: 1636			
Examiner Name: Gerald G. Letters Jr. <i>LAURA McGILLEN</i>			
SHEET	OF 2	Attorney Docket Number: 0380-P02709US0	

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1				


OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>LJM</i>	C1	Haque NS, LeBlanc CJ, Isaacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant. 1997 May-Jun;6(3):239-48.
<i>LJM</i>	C2	Åkerud P., Canals J., Snyder E.Y. and Arenas E. (2001) Neuroprotection through delivery of GDNF by neural stem cells in a mouse model of Parkinson's disease. Journal of Neuroscience, 21: 8108-8118.
<i>LJM</i>	C3	Åkerud P., Holm P.C., Castelo-Branco G., Sousa K., Rodriguez F.J. and Arenas E. (2002) Persephin-overexpressing neural stem cells regulate the function of nigrostriatal dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Molecular and Cellular Neuroscience, 21: 205-222.
<i>LJM</i>	C4	Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol. 2003 Oct;250 Suppl 3:III44-6.
<i>LJM</i>	C5	Dunnett SB, Björklund A, Lindvall O. (2001) Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci. 2001, 2(5):365-9.
<i>LJM</i>	C6	Von Bohlen und Halbach OB, Schober A, Kriegstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77.
<i>LJM</i>	C7	Schwarz J. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr Opin Neurol. 2003 Dec;16 Suppl 1:S27-33.

EXAMINER'S SIGNATURE	<i>Laura McGillem</i>	DATE CONSIDERED	7/13/05
----------------------	-----------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

U.S. PATENT & TRADEMARK OFFICE
INFORMATION
DISCLOSURE
STATEMENT



SHEET 2 OF 2

Complete if known

Application Number: 09/980,913

Filing Date: May 21, 2002

First Named Inventor: Ernest Arenas, et al.

Group Art Unit: 1636

Examiner Name: Gerald G. Leffers Jr. *Laura McGillem*

Attorney Docket Number: 0380-P02709US0

<i>JM</i>	C8	Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. <i>Nat Med.</i> 2003 May;9(5):589-95.
<i>JM</i>	C9	Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. <i>Science</i> 290(5492): 767-773.
<i>JM</i>	C10	Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R. Neural transplantation for the treatment of Parkinson's disease. <i>Lancet Neurol.</i> 2003 Jul;2(7):437-45.
<i>JM</i>	C11	Wagner J., Åkerud P., Castro D., Holm P C., Canals J M., Snyder E Y., Perlmann T. and Arenas E. (1999). Induction of a Midbrain Dopaminergic Phenotype in Nurr1-Overexpressing Neural Stem Cells. <i>Nature Biotechnology</i> , 17: 653-659
<i>JM</i>	C12	Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, Defer G, Samson Y, Peschanski M, Hantraye P, Cesaro P, Remy P. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. <i>Mov Disord.</i> 2003 Aug;18(8):928-32.
<i>JM</i>	C13	Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. <i>J Neuropathol Exp Neurol.</i> 2001 Aug;60(8):741-52.
<i>JM</i>	C14	Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ. Related Articles, Links Abstract Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Ann Neurol.</i> 2000 Nov;48(5):689-95.
<i>JM</i>	C15	KIRIK, D., et al., "Localized striatal delivery of GDNF as a treatment for Parkinson disease", <i>Nature Neuroscience</i> , vol. 7: p. 105-110, (2004).

EXAMINER'S SIGNATURE	<i>Laura McGillem</i>	DATE CONSIDERED	7/13/08
----------------------	-----------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.